Walleye Capital LLC Invests $424,000 in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)

Walleye Capital LLC acquired a new stake in shares of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRXGet Rating) in the first quarter, Holdings Channel reports. The firm acquired 8,576 shares of the specialty pharmaceutical company’s stock, valued at approximately $424,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. BlackRock Inc. lifted its holdings in Eagle Pharmaceuticals by 0.7% during the 1st quarter. BlackRock Inc. now owns 1,982,333 shares of the specialty pharmaceutical company’s stock valued at $98,105,000 after buying an additional 13,517 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Eagle Pharmaceuticals by 2.7% during the 1st quarter. Vanguard Group Inc. now owns 780,851 shares of the specialty pharmaceutical company’s stock valued at $38,644,000 after buying an additional 20,383 shares in the last quarter. State Street Corp lifted its holdings in Eagle Pharmaceuticals by 1.1% during the 1st quarter. State Street Corp now owns 715,884 shares of the specialty pharmaceutical company’s stock valued at $35,429,000 after buying an additional 7,660 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in Eagle Pharmaceuticals by 5.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 304,784 shares of the specialty pharmaceutical company’s stock valued at $15,084,000 after buying an additional 15,055 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in Eagle Pharmaceuticals by 2.8% during the 1st quarter. Renaissance Technologies LLC now owns 213,579 shares of the specialty pharmaceutical company’s stock valued at $10,570,000 after buying an additional 5,800 shares in the last quarter. Institutional investors own 88.49% of the company’s stock.

Insider Activity

In other news, Director Richard A. Edlin sold 6,800 shares of the business’s stock in a transaction dated Tuesday, September 6th. The shares were sold at an average price of $30.99, for a total value of $210,732.00. Following the completion of the sale, the director now owns 22,600 shares in the company, valued at approximately $700,374. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 28.20% of the company’s stock.

Eagle Pharmaceuticals Trading Up 0.9 %

Shares of EGRX opened at $27.13 on Friday. Eagle Pharmaceuticals, Inc. has a 1-year low of $26.21 and a 1-year high of $58.25. The company has a 50-day moving average of $36.08 and a 200 day moving average of $43.01. The firm has a market capitalization of $360.42 million, a price-to-earnings ratio of 15.41 and a beta of 0.66. The company has a debt-to-equity ratio of 0.12, a current ratio of 1.78 and a quick ratio of 1.25.

Eagle Pharmaceuticals (NASDAQ:EGRXGet Rating) last posted its quarterly earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported ($0.74) EPS for the quarter, missing the consensus estimate of $2.48 by ($3.22). Eagle Pharmaceuticals had a net margin of 8.37% and a return on equity of 11.18%. The business had revenue of $74.14 million during the quarter, compared to the consensus estimate of $108.13 million. On average, research analysts expect that Eagle Pharmaceuticals, Inc. will post 2.88 EPS for the current year.

Eagle Pharmaceuticals Profile

(Get Rating)

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.

Featured Stories

Want to see what other hedge funds are holding EGRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eagle Pharmaceuticals, Inc. (NASDAQ:EGRXGet Rating).

Institutional Ownership by Quarter for Eagle Pharmaceuticals (NASDAQ:EGRX)

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.